REVOLUTION MEDICINES INC. - COMMON STOCK

Revolution Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Update on Corporate Progress

27 Feb 2023 13:05:07 By Nasdaq GlobeNewswire

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2022 After Market Close on February 27, 2023

21 Feb 2023 13:05:16 By Nasdaq GlobeNewswire

Revolution Medicines to Participate in Upcoming Investor Conferences

02 Feb 2023 04:00:12 By Nasdaq GlobeNewswire

Revolution Medicines to Present at 41st Annual J.P. Morgan Healthcare Conference

03 Jan 2023 04:00:01 By Nasdaq GlobeNewswire

Revolution Medicines Announces Publication Describing Design and Synthesis of RMC-5552, a First-in-Class, Bi-Steric mTORC1-Selective Inhibitor

19 Dec 2022 04:00:00 By Nasdaq GlobeNewswire

Revolution Medicines to Regain Global Rights to RMC-4630 following Sanofi’s Termination of SHP2 Inhibitor Development and Commercialization Collaboration

07 Dec 2022 13:05:00 By Nasdaq GlobeNewswire

Revolution Medicines to Participate in Upcoming Investor Conferences

09 Nov 2022 13:05:01 By Nasdaq GlobeNewswire

Revolution Medicines Reports Third Quarter 2022 Financial Results and Update on Corporate Progress

07 Nov 2022 13:05:02 By Nasdaq GlobeNewswire

Revolution Medicines to Report Financial Results for Third Quarter 2022 After Market Close on November 7, 2022

01 Nov 2022 13:05:00 By Nasdaq GlobeNewswire

Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-6291, Company’s First Mutant-Selective RAS(ON) Inhibitor

22 Sep 2022 04:00:00 By Nasdaq GlobeNewswire

Revolution Medicines Strengthens Senior Management Team with Promotions and a New Hire

01 Sep 2022 13:05:00 By Nasdaq GlobeNewswire

Revolution Medicines to Participate in Upcoming Investor Conferences

31 Aug 2022 13:05:00 By Nasdaq GlobeNewswire

Revolution Medicines Reports Second Quarter 2022 Financial Results and Update on Corporate Progress

09 Aug 2022 13:02:00 By Nasdaq GlobeNewswire

Revolution Medicines to Report Financial Results for Second Quarter 2022 After Market Close on August 9, 2022

28 Jul 2022 13:02:00 By Nasdaq GlobeNewswire

Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

22 Jul 2022 13:02:00 By Nasdaq GlobeNewswire

Revolution Medicines Announces Pricing of Upsized $230.0 Million Public Offering of Common Stock

19 Jul 2022 19:41:52 By Nasdaq GlobeNewswire

Revolution Medicines Announces Commencement of Public Offering of Common Stock

19 Jul 2022 13:01:00 By Nasdaq GlobeNewswire

Revolution Medicines Appoints Lorence Kim, M.D., Accomplished Health Care Industry Leader, to Board of Directors

13 Jul 2022 04:00:00 By Nasdaq GlobeNewswire

Revolution Medicines Advances First RAS(ON) Inhibitor into Clinic, Dosing First Patient in Phase 1/1b Trial of RMC-6236

28 Jun 2022 04:00:00 By Nasdaq GlobeNewswire

Revolution Medicines to Participate in the 43rd Annual Goldman Sachs Global Healthcare Conference

09 Jun 2022 13:02:00 By Nasdaq GlobeNewswire